The Priority Review

Tag

PD-L1

1 story

  1. Clinical trials

    Pembrolizumab plus chemotherapy prolongs PFS versus monotherapy in high-PD-L1 NSCLC

    In the PERSEE phase III trial, 321 patients with stage IV or unresectable stage III NSCLC and PD-L1 ≥50% were randomized to pembrolizumab alone or with platinum-based chemotherapy. Median progression-free survival was 16.1 months with combination versus 6.9 months with monotherapy (HR 0.56, 95% CI 0.43-0.74; P<0.001).